Goodman Group’s AI Bet Faces an ASX Reality Check After Stock Slips

Goodman Group’s AI Bet Faces an ASX Reality Check After Stock Slips

June 8, 2026

Sydney, June 9, 2026, 04:05 AEST

Goodman Group shares head into Tuesday’s ASX restart at A$31.10, after a soft finish before the long weekend left investors weighing its fast-growing data-centre pipeline against delivery and funding risk. The stock last closed down 0.38%, according to the ASX company page.

The timing matters. There was no Monday cash-market trading to reset the price, with the ASX listing King’s Birthday on June 8 as a closed, no-settlement session.

Goodman lost about 1.8% over the week, while the S&P/ASX 200 fell 0.70% on Friday to 8,625.10 and was down roughly 1.2% for the week. The S&P/ASX 200 is the main institutional benchmark, meaning the yardstick used by many funds to judge Australian large-cap share performance.

The stock’s next move now rests less on the broad AI story and more on proof. Goodman said in its Q3 update that development work in progress, or the estimated value of projects being built, was A$14.5 billion at March 31 and was expected to reach about A$18 billion by June 2026; data centres accounted for 73% of that work, and its “power bank” — electricity capacity tied to current and future data-centre sites — stood at 6.4 gigawatts. Goodman

Chief Executive Greg Goodman said customer talks were advancing as supply stayed constrained by grid capacity, water, site complexity and capital intensity. He also said “equity capital is becoming more selective,” and the company remained on track for at least 9% operating earnings per security growth in FY26; operating EPS is a per-security profit measure based on underlying operations. Goodman

That was not enough for every investor. The Australian reported last week that Goodman’s securities fell 2.8% after the company reiterated, rather than lifted, guidance; Bell Potter analyst Andy MacFarlane said the group had repeated guidance while lifting its power bank by 7% to 6.4GW.

The peer read-through is mixed but relevant. NEXTDC, the ASX-listed data-centre operator and a key name investors use to track digital infrastructure demand, last closed at A$15.860, down 3.11%, showing the AI infrastructure trade has not been immune to selling.

Goodman is not just a data-centre punt. Its own site lists a A$87.1 billion total portfolio, 15 countries and 6.4GW of total power, and describes the group as providing logistics and data-centre infrastructure for the digital economy.

But the downside case is plain enough. If customer contracts take longer, power costs rise, or construction costs move against the group, the market could keep treating Goodman more like a developer taking execution risk than a defensive landlord. Its update also flagged negative rental reversion in China, meaning some rents there are resetting below previous levels, even as the wider portfolio stayed positive.

The week ahead is about evidence. Investors will be looking for customer commitments, capital-partner progress in Australia, or any fresh ASX filing that turns the data-centre pipeline into contracted income.

Until then, A$31.10 is the marker. The stock’s first trades after the holiday break will say whether investors still want to pay up for Goodman’s AI-linked growth, or whether they want clearer proof before pushing it back higher.

Stock Market Today

  • New Drug Apitegromab May Prevent Muscle Loss from Obesity GLP-1 Treatments
    June 8, 2026, 2:04 PM EDT. A new drug, apitegromab, shows promise in reducing muscle loss associated with GLP-1 obesity medications like Ozempic, Wegovy, and Mounjaro, which can cause unwanted muscle decline known as 'Ozempic butt.' In a six-month U.S. trial involving 102 adults, participants receiving apitegromab alongside Mounjaro retained 55% more muscle mass while still achieving fat loss. Muscle preservation is crucial since unlike fat, muscle is harder to regain. Apitegromab, administered via infusion, blocks a protein that triggers muscle breakdown and is under investigation for other muscle-related conditions. Experts urge caution, calling for larger and longer studies to confirm benefits such as improved strength and health outcomes. The treatments remain appetite suppressants and are not intended for short-term cosmetic use.